Intravitreal brolucizumab in neovascular age-related macular degeneration with limited response to aflibercept

被引：0
|
作者：
Hatz, Katja B. [1 ,2 ]
Cedro, Luca [1 ]
机构：
[1] Vista Klin AG, Binningen, Switzerland
[2] Univ Basel, Basel, Switzerland
来源：
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE | 2023年 / 64卷 / 08期
关键词：
D O I：
暂无
中图分类号：
R77 [眼科学];
学科分类号：
100212 ;
摘要：
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Bilateral occlusive vasculitis after intravitreal injection of brolucizumab in neovascular age-related macular degeneration
    Riedel, Anna Maria
    Lackerbauer, Carlo
    Lohmann, Chris P.
    Ulbig, Michael
    OPHTHALMOLOGIE, 2022, 119 (01): : 75 - 78
  • [42] Brolucizumab for Neovascular Age-Related Macular Degeneration (BEL Study)
    Van Cleemput, Liesbeth
    Peeters, Freya
    Jacob, Julie
    CLINICAL OPHTHALMOLOGY, 2023, 17 : 1077 - 1085
  • [43] Brolucizumab: an evolution in treatment for neovascular age-related macular degeneration
    Ong, Ee Lin
    Spooner, Kimberly
    Hong, Thomas
    Chang, Andrew
    EXPERT REVIEW OF OPHTHALMOLOGY, 2020, 15 (02) : 71 - 81
  • [44] CHANGES IN SYSTEMIC LEVELS OF VASCULAR ENDOTHELIAL GROWTH FACTOR AFTER INTRAVITREAL INJECTION OF AFLIBERCEPT OR BROLUCIZUMAB FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION
    Angermann, Reinhard
    Huber, Anna Lena
    Nowosielski, Yvonne
    Salcher, Stefan
    Gasser, Thomas
    Seifarth, Christof
    Kralinger, Martina T.
    Zehetner, Claus
    RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES, 2022, 42 (03): : 503 - 510
  • [45] Lamellar macular hole following intravitreal aflibercept injection in a patient with neovascular age-related macular degeneration
    Bagci, Fatma
    Citirik, Mehmet
    CUKUROVA MEDICAL JOURNAL, 2023, 48 (02): : 728 - 732
  • [46] Brolucizumab vs aflibercept and ranibizumab for neovascular age-related macular degeneration: a cost-effectiveness analysis
    Yu, Justin S.
    Carlton, Rashad
    Agashivala, Neetu
    Hassan, Tarek
    Wykoff, Charles C.
    JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2021, 27 (06): : 743 - 752
  • [47] Efficacy of Injection Interval Shortening in Neovascular Age-related Macular Degeneration with Limited Response to Bimonthly Aflibercept
    Kim, Min Chul
    Kim, Jae Hui
    JOURNAL OF THE KOREAN OPHTHALMOLOGICAL SOCIETY, 2023, 64 (08): : 700 - 708
  • [48] Intravitreal bevacizumab for neovascular age-related macular degeneration
    Ladewig, M. S.
    Ziemssen, F.
    Jaissle, G.
    Helb, H. -M.
    Scholl, H. P. N.
    Eter, N.
    Bartz-Schmidt, K. U.
    Holz, F. G.
    OPHTHALMOLOGE, 2006, 103 (06): : 463 - +
  • [49] Response of retinal pigment epithelial detachments to intravitreal aflibercept in neovascular age-related macular degeneration refractory ranibizumab
    Ogata, N.
    Hasegawa, T.
    Yamashita, M.
    Okamoto, M.
    ACTA OPHTHALMOLOGICA, 2013, 91
  • [50] COST-EFFECTIVENESS OF INTRAVITREAL AFLIBERCEPT IN TREATING NEOVASCULAR AGE-RELATED MACULAR DEGENERATION IN SWEDEN
    Clements, K. M.
    Hulbert, E. M.
    Panchmatia, H. R.
    Eriksson, M.
    Wittrup-Jensen, K. U.
    Nilsson, J.
    Weinstein, M. C.
    VALUE IN HEALTH, 2013, 16 (07) : A506 - A506
12345